CTOs on the Move

Quotient Sciences

www.seaviewresearch.net

 
Quotient Sciences is a drug development and manufacturing accelerator supporting customers from candidate selection to commercial launch.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details

Similar Companies

Jennerex Biotherapeutics

Jennerex Biotherapeutics is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galera Therapeutics

Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer.

Blue Sky Broadcast

Blue Sky Broadcast is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inkblot Therapy

Inkblottherapy.com offers affordable, secure video counselling any time, any place. We are on a mission to increase accessibility to high quality mental health counselling in Canada.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.